The role of remission induction and donor cells for outcome
| Response to initial chemotherapy (no. of patients) . | Secondary intervention . | Median OS after relapse, mo (95% CI) . | OS at 2 y after relapse, mo (SD) . |
|---|---|---|---|
| no CR (n = 89) | No donor cell no infusion, n = 53 | 2.6 (1.3-3.9) | 3.8 (± 3) |
| DLI, n = 28 (25 with active disease and 3 in aplasia) | 5.1 (3.5-6.64) | 3.8 (± 3) | |
| Second HSCT, n = 8 (all in refractory relapse) | 8.2 (6.7-9.5) | 18.8 (± 16) | |
| Any donor cell based therapy (DLI or second HSCT), n = 36 | 6.4 (4.5-8.3) | 6.3 (± 4) | |
| CR (n = 38) | No donor cell no infusion, n = 16 | 6.8 (5.1-8.4) | 20 (± 10) |
| DLI, n = 12 (1 with active disease; 1 MRD; 10 in CR) | 22.9 (0-49) | 50 (± 17) | |
| Second HSCT, n = 10 (9 in CR2; 1 in CR3) | 33 (4.5-61) | 60 (± 16) | |
| Any donor cell based therapy (DLI or second HSCT), n = 22 | 32.7 (11.8-53.5) | 55 (± 11) |
| Response to initial chemotherapy (no. of patients) . | Secondary intervention . | Median OS after relapse, mo (95% CI) . | OS at 2 y after relapse, mo (SD) . |
|---|---|---|---|
| no CR (n = 89) | No donor cell no infusion, n = 53 | 2.6 (1.3-3.9) | 3.8 (± 3) |
| DLI, n = 28 (25 with active disease and 3 in aplasia) | 5.1 (3.5-6.64) | 3.8 (± 3) | |
| Second HSCT, n = 8 (all in refractory relapse) | 8.2 (6.7-9.5) | 18.8 (± 16) | |
| Any donor cell based therapy (DLI or second HSCT), n = 36 | 6.4 (4.5-8.3) | 6.3 (± 4) | |
| CR (n = 38) | No donor cell no infusion, n = 16 | 6.8 (5.1-8.4) | 20 (± 10) |
| DLI, n = 12 (1 with active disease; 1 MRD; 10 in CR) | 22.9 (0-49) | 50 (± 17) | |
| Second HSCT, n = 10 (9 in CR2; 1 in CR3) | 33 (4.5-61) | 60 (± 16) | |
| Any donor cell based therapy (DLI or second HSCT), n = 22 | 32.7 (11.8-53.5) | 55 (± 11) |
SD indicates standard deviation.